Voyager Therapeutics presents data for Tracer platform

Voyager Therapeutics presented data related to its Tracer capsid discovery platform and Tracer-driven gene therapy programs at the American Society of Gene & Cell Therapy’s 27th annual meeting. Second-generation, intravenously -delivered capsids evolved through the Tracer platform, showed further enhanced blood-brain barrier penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions. Further, a gene therapy in preclinical development for SOD1 amyotrophic lateral sclerosis or ALS reduced SOD1 messenger RNA expression by up to 80% in non-human primate spinal cord motor neurons. The potential translatability of these capsids is supported by data across multiple species. The performance of these capsids has enabled selection of three development candidates in Voyager’s wholly-owned and partnered gene therapy programs for neurologic diseases, which are currently advancing towards anticipated IND filings in 2025. Additional data demonstrating the potential translatability, activity against therapeutic targets, manufacturability and performance of Voyager’s Tracer capsids are being presented across 12 oral and poster presentations throughout the ASGCT meeting.